Last $1.51 USD
Change Today -0.05 / -3.21%
Volume 104.1K
XXII On Other Exchanges
Symbol
Exchange
NYSE Amex
Stuttgart
As of 12:27 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

22nd century group inc (XXII) Snapshot

Open
$1.59
Previous Close
$1.56
Day High
$1.62
Day Low
$1.51
52 Week High
03/11/14 - $6.36
52 Week Low
12/15/14 - $1.51
Market Cap
97.1M
Average Volume 10 Days
271.5K
EPS TTM
$-0.19
Shares Outstanding
64.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for 22ND CENTURY GROUP INC (XXII)

Related News

No related news articles were found.

22nd century group inc (XXII) Related Businessweek News

No Related Businessweek News Found

22nd century group inc (XXII) Details

22nd Century Group, Inc., a plant biotechnology company, focuses on tobacco harm reduction and smoking cessation products produced from modifying the nicotine content in tobacco plants through genetic engineering and plant breeding. It develops smoking cessation products for smokers who are unable or unwilling to quit smoking; and modified risk tobacco products that reduce exposure to certain tobacco smoke toxins compared to conventional cigarettes. The company’s products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy; RED SUN and MAGIC regular and menthol cigarettes; and SPECTRUM government research cigarettes. It is also developing modified risk cigarettes, such as BRAND A, which has approximately 95% less nicotine than tobacco in cigarettes; and BRAND B cigarettes’ with smoke that contains the lowest amount of tar per milligram of nicotine. 22nd Century Group, Inc. was founded in 1998 and is based in Clarence, New York.

9 Employees
Last Reported Date: 01/30/14
Founded in 1998

22nd century group inc (XXII) Top Compensated Officers

President, Chief Operating Officer and Direct...
Total Annual Compensation: $159.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $83.1K
Vice President of R&D
Total Annual Compensation: $124.2K
Compensation as of Fiscal Year 2013.

22nd century group inc (XXII) Key Developments

22nd Century Group, Inc. - Shareholder/Analyst Call

To overview of recent business highlights and a summary of the company's plans for the first half of 2015

22nd Century Group, Inc. Presents at LD Micro Conference, Dec-03-2014 09:30 AM

22nd Century Group, Inc. Presents at LD Micro Conference, Dec-03-2014 09:30 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States.

22nd Century Group, Inc. Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

22nd Century Group, Inc. announced earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net loss of $2,724,309 or $0.05 per share compared to $15,372,517 or $0.32 per share a year ago. Adjusted LBITDA was $1,930,650 or $0.03 per share compared to $700,696 or $0.02 per share a year ago. Revenue was $64,000 compared to $52,500 a year ago. The revenues consist of $80,000 generated from the manufacture of filtered cigars, including $64,000 in the third quarter, with the remainder of the revenue generated from the sale of SPECTRUM research cigarettes to the National Institute on Drug Abuse (NIDA), which is part of the National Institutes of Health (NIH), United States Department of Health and Human Services. Operating loss was $2.82 million compared to $1.09 million a year ago. For the nine months, the company reported net loss of $10,005,252 or $0.17 per share compared to $18,331,675 or $0.44 per share a year ago. Adjusted LBITDA was $3,951,833 or $0.07 per share compared to $1,668,248 or $0.04 per share a year ago. Revenue was $528,000. Operating loss was $6.05 million compared to $4.10 million a year ago. The results for the nine months ended September 30, 2014 included non-operating expenses from a non-cash change in the fair value of derivatives (warrant liability) of $3.85 million, a non-cash inducement expense of $145,000 from the amendment of certain warrants, and other net non-operating income of $40,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XXII:US $1.51 USD -0.05

XXII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Japan Tobacco Inc ¥3,373 JPY -60.50
Lorillard Inc $63.68 USD +0.08
Perrigo Co PLC $165.68 USD -0.43
Reynolds American Inc $65.73 USD +0.28
Rock Creek Pharmaceuticals Inc $0.16 USD -0.0103
View Industry Companies
 

Industry Analysis

XXII

Industry Average

Valuation XXII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.1x
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 22ND CENTURY GROUP INC, please visit www.xxiicentury.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.